Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study
Real-World-Vergleich kurzfristiger unerwünschter Ereignisse, Therapiepersistenz und Wirksamkeit von Semaglutid und Tirzepatid: multizentrische landesweite Studie
Obesity Facts · 24.04.2026 · 1-17
DOI: 10.1159/000552104 ↗Auf einen Blick
In einer multizentrischen Beobachtungsstudie bei Menschen mit Adipositas waren Semaglutid und Tirzepatid kurzfristig ähnlich verträglich. Tirzepatid war mit stärkerem frühem Gewichtsverlust verbunden.
Fragestellung
Vergleich von Sicherheit, Verträglichkeit und Wirksamkeit von Semaglutid und Tirzepatid bei Adipositas in der Routineversorgung.
Methode
Landesweite multizentrische Beobachtungsstudie mit 2.549 Patient:innen; Vergleich von Semaglutid und Tirzepatid; Beobachtung bis 6 Monate; Subgruppen mit und ohne T2DM.
Ergebnisse
50,9 % unter Semaglutid und 51,0 % unter Tirzepatid hatten mindestens 1 unerwünschtes Ereignis (p = 0,524). Nach 6 Monaten betrug der mediane prozentuale BWL 12,6 % vs. 14,4 %; HbA1c-Senkungen waren bei T2DM vergleichbar.
Schlussfolgerung der Autor:innen
Semaglutid und Tirzepatid zeigten in der klinischen Routine eine ähnliche kurzfristige Verträglichkeit und Therapiepersistenz; Tirzepatid war mit mehr muskuloskelettalen und allergischen Reaktionen sowie stärkerem frühem BWL verbunden.
Kernaussagen
- Unerwünschte Ereignisse insgesamt ähnlich häufig: 50,9 % vs. 51,0 %
- Tirzepatid mit stärkerem frühem Gewichtsverlust
- Bei T2DM waren HbA1c-Senkungen vergleichbar
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Obesity Facts, online erschienen am 24.04.2026. Verfasst von Sema Hepşen und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Ankara Etlik City Hospital, Ankara, Turkey, semahepsen@gmail.com. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Introduction
Real-world data directly comparing the safety, tolerability, and effectiveness of semaglutide and tirzepatide in patients with obesity remain limited. This nationwide multicenter observational study compared short-term adverse events, treatment discontinuation, body weight loss (BWL), and metabolic outcomes between the two treatments.
Methods
This study included 2,549 patients with obesity treated with semaglutide (n = 1,434) or tirzepatide (n = 1,115). Adverse events, including time to onset, dose at occurrence, and related discontinuation, were evaluated. Changes in BWL and metabolic parameters up to 6 months were assessed. Subgroup analyses were performed in patients with and without type 2 diabetes mellitus (T2DM).
Results
At least one adverse event occurred in 50.9% in the semaglutide group and 51.0% in the tirzepatide group (p = 0.524), with gastrointestinal events the most frequently reported. Overall adverse event rates were comparable between groups; however, musculoskeletal and allergic reactions were more common in the tirzepatide group. The onset of gastrointestinal, neuropsychiatric, musculoskeletal symptoms, and hypoglycemia occurred earlier in the tirzepatide group. Discontinuation due to adverse events was similar between groups, except for pancreatic events, which were more frequent in the semaglutide group (p = 0.006). Tirzepatide was associated with greater early BWL at all time points. At 6 months, median percentage BWL was 12.6% with semaglutide and 14.4% with tirzepatide. HbA1c reductions were comparable between groups in patients with T2DM.
Conclusion
In real-world clinical practice, semaglutide and tirzepatide show similar short-term tolerability and treatment persistence, although tirzepatide is associated with a higher incidence of musculoskeletal and allergic reactions and greater early BWL.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Ankara Etlik City Hospital, Ankara, Turkey, semahepsen@gmail.com.
- Department of Endocrinology and Metabolism, Gülhane Training and Research Hospital, Ankara, Turkey.
- Department of Endocrinology and Metabolism, Ankara Etlik City Hospital, Ankara, Turkey.
- Department of Endocrinology and Metabolism, Ankara Atatürk Sanatoryum Training and Research Hospital, Ankara, Turkey.
- Department of Endocrinology and Metabolism, Abdurrahman Yurtaslan Training and Research Hospital, Ankara, Turkey.
- Department of Endocrinology and Metabolism, Ankara Güven Hospital, Ankara, Turkey.
Zitieren
APA
Hepşen, S., Haymana, C., Ertepe Küçükgöde, G., Özcan, B., Özbaş, B., Or Koca, A., Aydoğan, B. İ., Tura Bahadır, Ç., Durcan, E., Yumuk, V., Toros, B., Alphan Üç, Z., Önder, Ç. E., Karaca Karagöz, Z., Aşık, M., Öztürk, Y., Kocabaş, M., Karaköse, M., Bostan, H., …, & Soylu, H. (2026). Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study. Obesity Facts, 1-17. https://doi.org/10.1159/000552104
Vancouver
Hepşen S, Haymana C, Ertepe Küçükgöde G, Özcan B, Özbaş B, Or Koca A, et al. Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study. Obesity Facts. 2026:1-17. doi:10.1159/000552104
BibTeX
@article{Hepen2026,
author = {Hepşen, Sema and Haymana, Cem and Ertepe Küçükgöde, Gizem and Özcan, Büşra and Özbaş, Burak and Or Koca, Arzu and Aydoğan, Berna İmge and Tura Bahadır, Çiğdem and Durcan, Emre and Yumuk, Volkan and Toros, Bora and Alphan Üç, Ziynet and Önder, Çağatay Emir and Karaca Karagöz, Zuhal and Aşık, Mehmet and Öztürk, Yusuf and Kocabaş, Muhammet and Karaköse, Melia and Bostan, Hayri and Kıyıcı, Sinem and Salman, Serpil and Gogas Yavuz, Dilek and Göksoy Solak, Yağmur and Daloğlu, Osman Onur and Eren, Mehmet Ali and Doğanay, Şahin and Güven, Mehmet and Kaplan, Gizem Ilgın and Cesur, Mustafa and Demir Önal, Eda and Ertek Yalçın, Sibel and Ağbaht, Kemal and Baloğlu Akyol, Elif Melis and Genç, Selin and Özer, Özge and Şimşek, Yasin and Topaloğlu, Ömercan and Acıbucu, Fettah and Bozdoğan, Mehmet Emin and Karagün, Barış and Emral, Rıfat and Tan, Sinem Başak and İnce, Yahya Erdem and Akkuş, Gamze and Cansu, Güven Barış and Saltabaş, Mehmet Akif and Çakır, Bekir and Karaahmetli, Gülsüm and Alkan, Samet and Demirpençe, Mustafa and Taşkaldıran, Işılay and Tanrıkulu, Seher and Bozkırlı, Emre and Turgut, Seda and Dereli Akdeniz, Didem and Gültekin, Arif Cengiz and Cerit, Ethem Turgay and Omma, Tülay and Can, Bülent and Soylu, Hüseyin},
title = {Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study},
journal = {Obesity Facts},
year = {2026},
pages = {1--17},
doi = {10.1159/000552104}
}
EUVIMED